May 31, 2024 10:58 AM EDT

Novartis shares updated data for BTK inhibitor; Astellas resubmits BLA for cancer drug after CRL

Plus, news about Valar Labs, Pharming Group and Day One Pharmaceuticals:

Novartis outlines one-year data for BTK inhibitor: The drug, called remibrutinib,

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

No­var­tis shares up­dat­ed da­ta for BTK in­hibitor; Astel­las re­sub­mits BLA for can­cer drug af­ter CRL